CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Editas Medicine (EDIT – Research Report) today. The company’s shares closed yesterday ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type ...

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Caribou Biosciences (CRBU – Research ...

Technological advancements, particularly in gene editing techniques such as CRISPR-Cas9, have significantly enhanced the precision and efficiency of gene therapy approaches. Moreover, increased ...

A study concluded that the use of over-the-counter pain relievers is more effective than opioids for pain management after ...

Princess Kate Middleton opened up about the side effects of chemo when she visited the Royal Marsden Hospital in London, ...

Cathie Wood's ARK Investment Management adds to its stake in Tempus AI ( NASDAQ:TEM) after the stock tumbled nearly 14% on Monday, January 13 4:00 PM ET. The company announces preliminary ...